Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

计划入组 21 人 · 首次发布于 2015 年 5 月 19 日

Standard of Care Comparative Arm of Phase 1/2 Gene Therapy Trial DREPAMIR" in Severe Sickle Cell Disease Patients

计划入组 30 人 · 首次发布于 2026 年 8 月 7 日

Sleep Apnea in Sickle Cell Disease

计划入组 30 人 · 首次发布于 2018 年 11 月 27 日

Voxelotor(Oxbryta)

C₁₉H₁₉N₃O₃ · Rx

Pentoxifylline

C₁₃H₁₈N₄O₃ · Rx

Dipyridamole(Aggrenox, Persantine)

<dd class="col-xl-8 col-md-9 col-sm-8">C₂₄H₄₀N₈O₄</dd> · Rx

UNIVERSITY OF INDIANAPOLIS

United States

Vivid Seats

United States

INNER MONNGOLIA YILI INDUSTRIAL GROUP CO.,LTD.

China

Etavopivat Shows Promise in Reducing Vaso-Occlusive Events in Sickle Cell Disease

Lyfgenia Gene Therapy Shows Durable Vaso-Occlusive Event Resolution in SCD Trials

Hydroxyurea Shows Promise for Hemoglobin SC Disease Despite Safety Concerns